CION Ameerpet
Maintenance treatment is a tablet you take every day, at home, often for two or three years — so the side effects that matter are the ones you live alongside, not the ones that last an afternoon. Most are mild, most appear in the first two to three months, and most settle. The ones that are serious are usually picked up on a blood test before you feel anything at all.
Maintenance therapy differs from chemotherapy in the one way that shapes everything else: it is a tablet, taken every day, at home, often for two or three years. There is no infusion day and no obvious recovery week. Instead there is a background level of tiredness or queasiness that you live alongside, and that is the honest thing to prepare for before you start.
The pattern is reassuring once you know it. Most PARP inhibitor side effects appear in the first eight to twelve weeks, are mild to moderate, and ease as your body adjusts to the drug. Fatigue, nausea and a falling haemoglobin are the three you are most likely to notice. Serious problems are much less common, and the ones that matter most are picked up on a routine blood count before you feel anything — which is the whole reason for the monitoring schedule further down this page.
One more thing worth knowing on day one. A side effect is a reason to change the dose, not automatically a reason to give up the treatment. Pausing for a week and restarting lower is the routine response, and far more women continue that way than stop. If you are still deciding whether to start at all, read this alongside how PARP-inhibitor maintenance therapy works and who benefits.
Nausea and tiredness are usually worst in the first weeks and settle from around month three. Knowing that in advance makes the early weeks easier to sit out.
Much of the tiredness on this treatment is anaemia. PARP inhibitor anaemia and fatigue are treatable — often with a dose change, sometimes with iron, occasionally with a transfusion.
Low platelets and low white cells rarely announce themselves. They show up on the scheduled full blood count, which is why the count matters more than how you felt that week.
In the first-line maintenance trials that established PARP-inhibitor-class therapy in advanced ovarian cancer, most side effects were low grade and appeared within the first two to three months of starting. Anaemia was the most common severe side effect, and the usual response was not to abandon treatment but to pause it briefly and restart at a lower dose. Dose interruptions and dose reductions were common in those trials; stopping permanently because of side effects was much less common, and the benefit of maintenance therapy was seen across the whole treated group, including the many women whose dose had been reduced. Source: SOLO-1 (Moore et al., New England Journal of Medicine, 2018); PRIMA (González-Martín et al., New England Journal of Medicine, 2019); NCCN Ovarian Cancer guidelines.
Listed roughly in order of how often women report them. For each one, your oncologist is answering the same three questions: is this the drug, is it something else, and does the dose need to change?
This is tiredness that sleep does not fix. It tends to build over the first few weeks, plateau, and then improve. Some of it is the drug acting directly. A good deal of it is anaemia. And some of it is the accumulated cost of surgery and months of platinum-based chemotherapy, which does not disappear the day maintenance therapy begins.
Before assuming it is the tablet, your team will check haemoglobin, thyroid function, kidney and liver function, and vitamin B12 and folate, because each has a specific fix. Where the drug is the cause, a dose reduction usually helps within two to three weeks. Light daily activity, short walks rather than long rests, and a steady sleep routine help more than they sound like they should.
Anaemia is the most common severe side effect of this drug class and the commonest reason a dose is changed. It develops gradually, usually within the first three months, and shows itself as breathlessness climbing stairs, palpitations, dizziness on standing, or the fatigue described above. It is measured, not guessed — which is why the blood-count schedule is not negotiable.
The response is graded. A mild fall may simply be watched. A larger fall means pausing the tablet until the count recovers, then restarting at a lower dose. Iron, vitamin B12 or folate is replaced where a deficiency is contributing. Where haemoglobin falls far enough to cause real symptoms, a red-cell transfusion is given and works quickly. Anaemia on maintenance therapy is common and manageable, and it is not a sign that the cancer is progressing.
Nausea is common in the first weeks and is usually mild — a background queasiness rather than vomiting. Appetite often drops with it, and food can taste metallic or simply wrong. Most of this settles by the second or third month.
Practical measures do most of the work. Take the tablet at night, after food, so you sleep through the worst of it. Eat small amounts often rather than three large meals. Anti-sickness medication is prescribed freely and is meant to be taken regularly through the difficult weeks, not saved for emergencies. Tell your team if you are vomiting, because a tablet that comes back up is a dose not taken, and repeated vomiting needs a different plan rather than persistence.
These are found on the blood count rather than felt. Low platelets show up as easy bruising, nosebleeds or bleeding gums; low white cells carry no symptoms at all until an infection arrives, which is why fever on this treatment is always taken seriously. Both are commonest in the first two months.
Both are handled the same way: pause, let the count recover, restart at a lower dose. Some agents in this class set the starting dose by body weight and platelet count precisely to reduce this risk. If your platelets are low, avoid anti-inflammatory painkillers, and tell any dentist or surgeon that you are on maintenance therapy before a procedure.
One of the agents in this drug class can raise blood pressure and resting heart rate. Where that agent is used, blood pressure and pulse are checked at each visit, often weekly for the first two months and monthly after that, and a home monitor is worth having.
A rise is treatable with standard blood-pressure medication and is rarely a reason to stop maintenance therapy. What needs same-day attention is a severe headache, chest pain, a visual change or a persistently racing heart, because those need assessment rather than a dose adjustment at the next visit.
Bowel changes are common and usually mild. Constipation is more frequent than diarrhoea, and is often made worse by anti-sickness medication, eating and drinking less, and moving less. Loose stools and mild abdominal cramping occur in a minority of women.
Fluids, fibre and movement come first, with a stool softener or laxative added early rather than after a week of discomfort. Diarrhoea lasting more than two days, or coming with fever or abdominal pain, should be reported rather than self-treated. Many of the same practical measures used for chemotherapy side effects in ovarian cancer apply here too.
Pneumonitis — inflammation of the lung tissue itself — is a rare but recognised side effect of this drug class. It presents as a new dry cough, breathlessness worse than your haemoglobin would explain, or a low-grade fever, and it can develop at any point in treatment rather than only at the start.
It matters because it is treatable when caught early and dangerous when ignored. New or worsening breathlessness, or a persistent dry cough, should be reported the same day. Assessment usually means oxygen saturation, a chest X-ray or CT, and tests to exclude infection and clots, which are commoner explanations. Treatment is to hold the drug and, where pneumonitis is confirmed, give steroids.
Myelodysplastic syndrome and acute myeloid leukaemia are serious blood disorders reported in a small number of women on this drug class, at rates of around one in a hundred or lower in the maintenance trials. They occur most often in women who have already had several lines of platinum-based chemotherapy, which carries the same risk on its own, and they typically appear a year or more into treatment.
The practical implication is that blood counts continue to matter, including after maintenance therapy ends. A count that stays low, or falls without an obvious explanation, is referred to a haematologist for assessment rather than watched indefinitely. This risk is real, it is uncommon, and it should be weighed openly against the benefit of delaying recurrence when the decision to start is made.
Most side effects can wait for your next scheduled visit. These six should not. None of them means the treatment has failed, and none of them is a reason to stop the tablet on your own before speaking to someone.
Particularly if it is new, worsening, or worse than your haemoglobin explains. This needs assessment the same day, not at the next appointment.
A temperature above 38°C on treatment is treated as an emergency until infection is excluded, because your white cells may be low without warning.
Nosebleeds, bleeding gums, blood in urine or stool, or bruises appearing without injury. All point to a low platelet count that needs checking now.
Assess rather than adjust. Chest pain, a persistently fast pulse or a severe headache needs to be seen, not managed over the phone.
A dose that comes back up is a dose not taken. Repeated vomiting needs a different anti-sickness plan rather than persistence.
Often significant anaemia, and confirmed with one blood test. It is treatable, and treatable quickly, once someone has measured it.
Keep your treatment card and your most recent blood-count report with you, and show them at any hospital you attend, including for something unrelated. If you cannot reach your treating team, attend the nearest emergency department rather than waiting — and request a callback so your CION team can pick the plan up afterwards.
If tiredness, nausea or a low blood count is making maintenance therapy hard to continue, that is a conversation to have this week rather than next month. Most of the time the answer is a short pause and a lower dose, not stopping.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation — including if you started maintenance therapy somewhere else and want a second opinion on the dose.
Monitoring on this treatment is not box-ticking. Each test exists because it changes a decision — usually whether the dose stays the same, pauses or drops.
| What is checked | How often | Why, and what changes if it is abnormal |
|---|---|---|
| Full blood count | Weekly for the first month with some agents; monthly through the first year; periodically after that. | Detects anaemia, low platelets and low white cells before symptoms appear. An abnormal count triggers a pause, then a restart at a lower dose. |
| Iron studies, vitamin B12, folate | When anaemia develops, before assuming the drug is the only cause. | A correctable deficiency is treated directly, which sometimes avoids a dose reduction altogether. |
| Blood pressure and heart rate | At every visit; weekly for the first two months with the agent in this class that raises them. | A rise is treated with standard blood-pressure medication rather than by stopping maintenance therapy. |
| Kidney and liver function | Before starting, then periodically. | Reduced kidney function affects how the drug is cleared and can change the starting dose. |
| A structured symptom review | At each monthly visit, and whenever you call in between. | Fatigue, nausea and bowel symptoms are graded so a dose change rests on a trend rather than one bad week. |
| Blood counts after treatment ends | Continued at follow-up visits. | A count that stays low, or falls without explanation, is referred for haematology assessment rather than watched indefinitely. |
*Exact schedules differ between the agents in this drug class and are set by your treating oncologist. CA-125 and scans, where they are part of your follow-up, track the cancer rather than the side effects — keep those two questions separate, because a rising CA-125 and a falling haemoglobin mean entirely different things.
Maintenance therapy is medical oncology, and medical oncology is what CION delivers in-house. The prescription, the monthly blood counts, the dose decisions and the follow-up all happen at CION, across 35+ centres in Telangana and Andhra Pradesh. That matters more than it sounds: this is a treatment measured in years, and a blood test close to home is often the difference between staying on it and quietly drifting off it.
BRCA and HRD testing and genetic counselling are in-house too, and they are what decide whether maintenance therapy is the right treatment for you in the first place. Ovarian cancer surgery, HIPEC and PET-CT are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there — we say that plainly rather than letting you find it out later.
The first consultation is free and runs about 45 minutes. That is long enough to go through your blood-count trend, your histopathology and your genetic results properly, which is what a dose decision actually rests on. If you started maintenance therapy elsewhere and are struggling with side effects, a second opinion on the dose is a reasonable thing to ask for, and you need no referral to get one. Where the honest answer is that treatment should be paused or stopped, you will be told that plainly, along with the other options open to you.
Free, unhurried, and long enough to review the blood-count trend and the pathology that a dose decision actually depends on.
Monthly counts and reviews at whichever of the 35+ centres is closest to you, rather than a trip into the city every month for years.
Medical oncology, pathology and imaging review the plan together — including the decision to reduce, pause or stop maintenance therapy.
BRCA and HRD testing with genetic counselling in-house, because eligibility for maintenance therapy is settled by those results, not by preference.
Fatigue, nausea and anaemia are reported most often, followed by reduced appetite, altered taste, constipation and mild abdominal discomfort. Falls in platelet and white-cell counts are less common and are usually found on a routine blood test rather than felt. Most of these are mild to moderate, appear within the first two to three months of starting, and ease as your body adjusts. Anaemia is the side effect most likely to become significant, and the commonest reason a dose is changed. Serious side effects, including inflammation of the lung tissue and bone-marrow disorders, are rare. The pattern matters as much as the list: side effects that begin late, or that worsen after months of stability, are worth reporting rather than assuming they are simply part of treatment.
Frequently at first, then less often. With some agents in this class the full blood count is checked weekly for the first month, because that is when counts are most likely to fall. After that it is usually monthly through the first year, and periodically thereafter. Blood pressure and heart rate are checked at every visit, and weekly for the first two months where the agent used can raise them. Kidney and liver function are checked before starting and periodically after. The exact schedule differs between agents, and your oncologist will set yours. These tests are the reason problems are caught before they cause harm, so a missed count is worth rescheduling rather than skipping. At CION the counts can be done at whichever centre is nearest to you.
For most women it improves. Fatigue tends to build over the first few weeks, plateau, then ease from around the third month. Before accepting it as permanent, your team will look for a treatable cause: anaemia is the commonest, and thyroid problems, low vitamin B12, low folate and poor sleep all contribute. Where the drug itself is responsible, a dose reduction usually helps within two to three weeks. Some background tiredness does persist for some women, particularly after major surgery and months of platinum-based chemotherapy, and that is worth saying honestly. It is also worth saying that light daily activity helps more than rest does, and that tiredness you can live with is a reasonable trade for delaying recurrence.
Usually not. The standard response to a troublesome side effect is to pause the tablet until things recover, then restart at a lower dose. In the maintenance trials, dose interruptions and reductions were common, while stopping permanently because of side effects was much less common, and the benefit was seen across the treated group including women whose dose had been reduced. A lower dose is not a watered-down treatment. What is not safe is deciding alone to stop, halve or skip doses, because the dose and the monitoring schedule are set together. If a side effect is making daily life hard, call your team rather than quietly stopping. Treatment is stopped for good only for a serious problem such as confirmed pneumonitis, a bone-marrow disorder, or counts that do not recover after a pause.
It is a real but uncommon risk, and it deserves a straight answer. Myelodysplastic syndrome and acute myeloid leukaemia have been reported in a small number of women on this drug class in the maintenance trials, at rates of around one in a hundred or lower. They occur most often in women who have already had several lines of platinum-based chemotherapy, which carries the same risk on its own, and they usually appear a year or more into treatment. Practically, this is why blood counts continue at follow-up visits even after maintenance therapy ends, and why a count that stays low or falls without an obvious cause is referred to a haematologist rather than watched. Your oncologist should weigh this openly against the benefit of delaying recurrence before you start.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, which covers chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with the BRCA and HRD testing and genetic counselling that decide whether maintenance therapy is right for you. Monthly blood counts and dose reviews can be done at the centre nearest your home. Debulking surgery, HIPEC and PET-CT are coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board rather than decided by one doctor. Second opinions on a dose started elsewhere are welcome and need no referral.